STAT+: Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field

The FDA's shifts are a top concern for the gene therapy field, even at a meeting in Rome. Recent approvals of rare disease treatments have been highlighted as reasons for optimism. The departure of Vinay Prasad, the FDA's vaccine chief, is also seen as potentially promising.